E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Ulcerative colitis (UC) and Crohn disease (CD) |
Colite ulcerosa (UC) e malattia di Crohn (CD) |
|
E.1.1.1 | Medical condition in easily understood language |
Inflammatory bowel diseases |
Malattie infiammatorie intestinali |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10017947 |
E.1.2 | Term | Gastrointestinal disorders |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the expression of α4β7 heterodimer in circulating T lymphocytes (CD4 and CD8) from active IBD patients and healthy controls, in combination with chemokine receptors known to define specific inflammatory and regulatory T cell subsets (Th1,Th17,Th1-17,Tc1,Tc17,Tregs) |
Valutare l'espressione dell’eterodimero α4β7 su linfociti T (CD4 e CD8) circolanti in pazienti con IBD attiva ed in controlli sani, in combinazione con molecole di superficie utili a definire subset specifici di cellule T infiammatorie e regolatorie (Th1, Th17, Th1-17, Tc17, Treg) |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the expression of α4β7 in gut-infiltrating T lymphocytes (CD4 and CD8 subsets) of active IBD patients and controls and to correlate the relative frequencies of circulating and gut-infiltrating α4β7-expressing T cell subsets at baseline with the short-term (14 week) clinical and endoscopical response to Vedolizumab |
Valutare l'espressione dell’eterodimero α4β7 in linfociti T intestinali (CD4 e CD8) in pazienti con IBD attiva e controlli e correlare la frequenza relativa di subset T linfocitari α4β7-positivi prima della terapia con la risposta clinica ed endoscopica a breve termine (12 settimane) alla terapia con Vedolizumab |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Key Inclusion Criteria (IBD patients): Patients with Crohn´s disease and ulcerative colitis qualified for vedolizumab therapy can be included.
Key Inclusion Criteria (healthy controls): Healthy subject between 18 and 80 years old doing colonoscopy either for colorectal cancer screening or gastrointestinal symptoms
|
Criteri di inclusione – pazienti IBD Pazienti adulti (18-80 anni) Diagnosi confermata di malattia di Crohn o colite ulcerosa da almeno 6 mesi HBI > 7 al basale o Mayo score > 6 e < 12 SES-CD > 2 al basale Punteggio Mayo parziale endoscopico > 1 Assunzione di tiopurine, se in dose stabile negli ultimi 4 mesi
Criteri di inclusione – soggetti sani Soggetti adulti (18-80 anni) sottoposti ad ileocolonscopia a fini di screening del cancro colorettale o per sintomi gastrointestinali
|
|
E.4 | Principal exclusion criteria |
Key Exclusion Criteria (IBD patients): 1. Subjects <18 years or > 80 years 2. History of malignancy in the previous 5 years 3. Serious infections within 4 weeks prior to baseline or active chronic infections 4. Pregnancy or lactation 5. Any medical condition that could negatively impact on the participation to the study 6. Therapy with any investigational or approved biologics within the last 60 days
Key Exclusion Criteria (healthy controls): 1. Subjects <18 years or > 80 years 2. Serious infections within 4 weeks prior to baseline or active chronic infections 3. Pregnancy or lactation 4. Any medical condition that could negatively impact on the participation to the study, in particular previous diagnosis of cancer or IBD. 5. Endoscopic signs of intestinal inflammation at baseline endoscopy, or detection of adenoma or colorectal cancer at screening endoscopy.
|
Criteri di esclusione - pazienti IBD Soggetti > 80 anni o < 18 anni Storia di neoplasia maligna nei 5 anni precedenti Gravi infezioni entro 4 settimane prima dello screening o infezioni croniche attive Gravidanza o allattamento Qualsiasi condizione medica che potrebbe incidere negativamente sulla partecipazione allo studio Terapia con antiTNF negli ultimi 60 giorni
Criteri di esclusione – soggetti sani Soggetti > 80 anni o < 18 anni Gravi infezioni entro 4 settimane prima dello screening o infezioni croniche attive Gravidanza o allattamento Qualsiasi condizione medica che potrebbe incidere negativamente sulla partecipazione allo studio, in particolare precedente diagnosi di tumore o IBD. Segni endoscopici di infiammazione intestinale all'endoscopia basale o rilevazione di adenoma o cancro colorettale all'endoscopia di screening.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
to correlate the relative frequencies of circulating and gut-infiltrating α4β7-expressing T cell subsets at baseline with the short-term (14 week) clinical and endoscopical response to Vedolizumab |
correlare la frequenza relativa di subset T linfocitari α4β7-positivi circolanti e intestinali prima della terapia con la risposta clinica ed endoscopica a breve termine (14 settimane) alla terapia con Vedolizumab |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
to evaluate the expression of α4β7 in gut-infiltrating T lymphocytes (CD4 and CD8 subsets) of active IBD patients and controls; |
valutare l'espressione dell’eterodimero α4β7 in linfociti T intestinali (CD4 e CD8) in pazienti con IBD attiva e controlli; |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
to evaluate predictive factors for the efficacy of the therapy |
valutazione fattori prognostici di risposta |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 24 |